Purpose/objectives: To determine women's satisfaction and experience with breast cancer screening and associated factors.

Design: Exploratory, descriptive design.

Setting: One center of the Ontario Breast Screening Program, a province-wide breast cancer screening program.

Sample: Nonprobability sample of 315 asymptomatic women, age 50 years or older, with no previous history of breast malignancy.

Methods: Data were collected from the entire sample of 315 women immediately postscreening using a self-report questionnaire and from a subgroup of 256 women by telephone interview at three weeks post-screening.

Main Research Variables: Satisfaction with and intentions and anxiety regarding breast cancer screening.

Findings: Overall, women reported a high level of satisfaction with their screening experience, including respect for privacy, encouragement to ask questions, and provision of information. Two areas of concern that participants identified were mammogram discomfort and fear about radiation risks. At the postscreening interview, women reported that breast screening had relatively little impact on social or physical aspects of their lives, but it did have a positive effect on certain emotional issues, such as their feelings of reassurance, well-being, and relaxation.

Conclusion: Since the degree of satisfaction that participants in health services report has been shown to influence attendance patterns, assessing breast screening programs from the perspective of attendees is necessary. Such assessment can identify areas of satisfaction and concern and, thus, provide information for developing interventions aimed at promoting recruitment and retention.

Implications For Nursing Practice: As health educators, nurses play an important role in providing breast cancer screening information to women. As well as being knowledgeable about screening guidelines and the benefits of screening, nurses also must recognize women's concerns about radiation risks and pain or discomfort with the procedure and be prepared to provide teaching and support for these women.

Download full-text PDF

Source

Publication Analysis

Top Keywords

breast cancer
20
cancer screening
16
breast screening
12
screening
10
breast
9
women
8
sample 315
8
women reported
8
radiation risks
8
cancer
5

Similar Publications

CXCR4 promotes tumor stemness maintenance and CDK4/6 inhibitors resistance in ER-positive breast cancer.

Breast Cancer Res

January 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.

Background: CDK4/6 inhibitors have significantly improved the survival of patients with HR-positive/HER2-negative breast cancer, becoming a first-line treatment option. However, the development of resistance to these inhibitors is inevitable. To address this challenge, novel strategies are required to overcome resistance, necessitating a deeper understanding of its mechanisms.

View Article and Find Full Text PDF

Background: Patients who actively engage in their medical decision-making processes can experience better health outcomes. This exploratory study aimed to identify predictors of preferred and actual roles in decision-making in healthy women with BRCA1/2 pathogenic variants (PVs).

Methods: Women with BRCA1/2 PVs without a history of breast and/or ovarian cancer were recruited in six centres across Germany.

View Article and Find Full Text PDF

Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630.

Invest New Drugs

January 2025

UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.

Background: Since MYC is one of the most frequently altered driver genes involved in cancer formation, it is a potential target for new anti-cancer therapies. Historically, however, MYC has proved difficult to target due to the absence of a suitable crevice for binding potential low molecular weight drugs.

Objective: The aim of this study was to evaluate a novel molecular glue, dubbed GT19630, which degrades both MYC and GSPT1, for the treatment of breast cancer.

View Article and Find Full Text PDF

Purpose: Build machine learning (ML) models able to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients based on conventional and radiomic signatures extracted from baseline [F]FDG PET/CT.

Material And Methods: Primary tumor and the most significant lymph node metastasis were manually segmented in baseline [F]FDG PET/CT of 52 newly diagnosed BC patients. Clinical parameters, NAC and conventional semiquantitative PET parameters were collected.

View Article and Find Full Text PDF

Micropeptide hSPAR regulates glutamine levels and suppresses mammary tumor growth via a TRIM21-P27KIP1-mTOR axis.

EMBO J

January 2025

Department of Geriatrics, Gerontology Institute of Anhui Province, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.

mTOR plays a pivotal role in cancer growth control upon amino acid response. Recently, CDK inhibitor P27KIP1 has been reported as a noncanonical inhibitor of mTOR signaling in MEFs, via unclear mechanisms. Here, we find that P27KIP1 degradation via E3 ligase TRIM21 is inhibited by human micropeptide hSPAR through its C-terminus (hSPAR-C), causing P27KIP1's cytoplasmic accumulation in breast cancer cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!